Navigation Links
Quintessence cancer treatment chosen for clinical studies

Madison, Wis. - Quintessence Biosciences, a biopharmaceutical company developing cancer therapies, has announced that QB139, one of its EVade cancer treatments, has been selected for preclinical testing and human clinical trials.

Quintessence said that pending a favorable preclinical safety assessment, it would submit to the

Source:wistechnology.com By WTN News 11/09/06


Page: 1

Related biology technology :

1. Quintessence Biosciences advances cancer drug
2. Quintessence Biosciences names new president
3. Quintessence division to develop drug tests with NIH grant
4. Quintessence Biosciences forms cancer therapeutic advisory board
5. Quintessence Secures Financing
6. NeoClone gets $750K for ovarian cancer detection
7. Medical College receives $1.4M cancer grant
8. GE Healthcare partners with UNC on breast cancer imaging research
9. Lance Armstrong and the future of cancer care
10. Medical College part of $5M cancer study
11. UW finds new path to anti-cancer agents
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/3/2016)... 2016  Discovery Laboratories, Inc. (NASDAQ: DSCO ... KL4 surfactant therapies for respiratory diseases, today announced ... inducement award as a component of employment compensation ... President and Chief Executive Officer.  The award was ... 1, 2016 and granted as an inducement material ...
(Date:2/3/2016)... Ascendis Pharma A/S (Nasdaq: ASND ), ... TransCon technology to address significant unmet medical needs, today ... Leerink Partners Global Healthcare Conference Location: , Waldorf ... 2016 Time:  , 11:55am EST www.ascendispharma.com ... An audio webcast of this event will be posted ...
(Date:2/3/2016)... , Feb. 3, 2016 New ... more than $1 million for researchers in ... on health-related research that demonstrates exciting potential.   ... of funding for the New Jersey Health Foundation Research ... members at these educational institutions— Princeton University, Rutgers ...
(Date:2/3/2016)... ... 2016 , ... ProMIS Neurosciences is currently in the process ... propagating strains of Amyloid beta involved in Alzheimer’s disease. The Company plans to ... on from the first misfolded Amyloid beta target announced on Nov. 12, 2015, ...
Breaking Biology Technology:
(Date:1/11/2016)... CHICAGO , Jan. 11, 2016  higi, ... via nearly 10,000 retail locations, web and mobile, ... than $40 million from existing investors. ... will be devoted to further innovate higi,s health ... app and web portal – including expanding services ...
(Date:1/7/2016)... -- This BCC Research report studies the global as ... identifying newer markets and exploring the expansion of the ... Includes forecast from 2015 to 2020. Use ... the expansion of the present application market for various ... technology, determine its current market size, and estimate the ...
(Date:1/6/2016)... 2016  Varam Capital, a provider of micro-finance inclusion ... deliver advanced authentication solutions to their clients. Varam supplies ... A loan of a few thousand rupees may make ... ability to purchase livestock or equipment for a small ... for a local store. ...
Breaking Biology News(10 mins):